Surrogate markers in clinical trials-Challenges and opportunities

Atherosclerosis

Volumn 206, Issue 1, 2009, Pages 8-16

  Duivenvoorden, Raphaël ^a   de Groot, Eric ^a   Stroes, Erik S G ^a   Kastelein, John J P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Atherosclerosis; Cardiovascular disease; Plasma biomarker; Surrogate endpoint; Vascular imaging

Indexed keywords

ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; COLESTIPOL; EZETIMIBE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MIPOMERSEN; NICOTINIC ACID; PACTIMIBE; PLACEBO; PRAVASTATIN; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; SULFONYLUREA DERIVATIVE; TORCETRAPIB;

ARTERY BLOOD FLOW; ARTERY WALL; ARTIFACT REDUCTION; ATHEROSCLEROSIS; B SCAN; BRACHIAL ARTERY; CLINICAL RESEARCH; CLINICAL TRIAL; DISEASE MARKER; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG RESPONSE; DRUG TARGETING; HUMAN; HYPERCHOLESTEROLEMIA; INTRAVASCULAR ULTRASOUND; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; VASODILATATION;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BRACHIAL ARTERY; CARDIOVASCULAR AGENTS; CAROTID ARTERIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; CORONARY VESSELS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MAGNETIC RESONANCE IMAGING; REGIONAL BLOOD FLOW; RESEARCH DESIGN; TUNICA INTIMA; VASODILATION;

EID: 68949220300     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.12.009     Document Type: Review

References (72)

1. Tavridou A., and Manolopoulos V.G. Novel molecules targeting dyslipidemia and atherosclerosis. Curr Med Chem 15 (2008) 792-802
2. Krumholz H.M., and Lee T.H. Redefining quality-implications of recent clinical trials. N Engl J Med 358 (2008) 2537-2539
3. NIH Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69 (2001) 89-95
4. Boissel J.P., Collet J.P., Moleur P., and Haugh M. Surrogate endpoints: a basis for a rational approach. Eur J Clin Pharmacol 43 (1992) 235-244
5. Smilde T.J., Wollersheim H., Van L.H., and Stalenhoef A.F. Reproducibility of ultrasonographic measurements of different carotid and femoral artery segments in healthy subjects and in patients with increased intima-media thickness. Clin Sci (Lond) 93 (1997) 317-324
6. Hansson G.K., and Inflammation. atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
7. Kannel W.B., Castelli W.P., and Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med 90 (1979) 85-91
8. Castelli W.P. Cholesterol and lipids in the risk of coronary artery disease-the Framingham Heart Study. Can J Cardiol 4 Suppl. A (1988) 5A-10A
9. Law M.R., Wald N.J., and Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326 (2003) 1423
10. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 288 (2002) 321-333
11. Kastelein J.J., Akdim F., Stroes E.S., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358 (2008) 1431-1443
12. Stein E.A. After ENHANCE: is more LDL cholesterol lowering even better?. Clin Chem 54 (2008) 940-942
13. Smilde T.J., van W.S., Wollersheim H., Trip M.D., Kastelein J.J., and Stalenhoef A.F. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357 (2001) 577-581
14. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 (1989) 8-15
15. Canner P.L., Berge K.G., Wenger N.K., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 8 (1986) 1245-1255
16. Birjmohun R.S., Hutten B.A., Kastelein J.J.P., et al. Increasing HDL cholesterol with extended release nicotinic acid: from promise to practice. Neth J Med 62 (2004) 229-234
17. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007) 2109-2122
18. Vergeer M, Bots ML, van Leuven SI, et al. The CETP inhibitor torcetrapib and off-target toxicity: a pooled analysis of the RADIANCE trials. Circulation; in press.
19. Forrest M.J., Bloomfield D., Briscoe R.J., et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 154 (2008) 1465-1473
20. Stroes E.S., Kastelein J.J., and Bernardeau A. Absence of effect of R1658/JTT-705 on blood pressure and tissue expression of renin-angiotensin system related genes in rats. J Am College Cardiol 51 Suppl. 1 (10) (2008) A322
21. Selvin E., Marinopoulos S., Berkenblit G., et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141 (2004) 421-431
22. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008) 2545-2559
23. Kahn S.E., Haffner S.M., Heise M.A., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 (2006) 2427-2443
24. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
25. Rosen C.J. The rosiglitazone story-lessons from an FDA advisory committee meeting. N Engl J Med 357 (2008) 844-845
26. Tobis J.M., Mallery J., Mahon D., et al. Intravascular ultrasound imaging of human coronary arteries in vivo. Analysis of tissue characterizations with comparison to in vitro histological specimens. Circulation 83 (1991) 913-926
27. Mintz G.S., Nissen S.E., Anderson W.D., et al. American College of Cardiology Clinical Expert Consensus Document on Standards for acquisition, Measurement and Reporting of intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 37 (2001) 1478-1492
28. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
29. Taylor A.J., Kent S.M., Flaherty P.J., Coyle L.C., Markwood T.T., and Vernalis M.N. ARBITER: arterial biology for the investigation of the treatment effects of reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 106 (2002) 2055-2060
30. Nissen S.E., Nicholls S.J., Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295 (2006) 1556-1565
31. Nissen S.E., Tardif J.C., Nicholls S.J., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356 (2007) 1304-1316
32. Kastelein J.J., van Leuven S.I., Burgess L., et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 356 (2007) 1620-1630
33. Bots M.L., Visseren F.L., Evans G.W., et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 370 (2007) 153-160
34. Nicholls S.J., Sipahi I., Schoenhagen P., et al. Intravascular ultrasound assessment of novel antiatherosclerotic therapies: rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study. Am Heart J 152 (2006) 67-74
35. Meuwese M.C., Duivenvoorden R., Davidson M.D., et al. Effect of ACAT inhibition on progression of carotid atherosclerosis in patients with familial hypercholesterolemia, the CAPTIVATE study. J Clin Lipidol 1 (2007) 382
36. von Birgelen B.C., Hartmann M., Mintz G.S., et al. Relationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries. Circulation 110 September (12) (2004) 1579-1585
37. Pignoli P., Tremoli E., Poli A., Oreste P., and Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 74 (1986) 1399-1406
38. Lorenz M.W., Markus H.S., Bots M.L., Rosvall M., and Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115 (2007) 459-467
39. Byington R.P., Furberg C.D., Crouse III J.R., Espeland M.A., Bond M.G., and Pravastatin. Lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 76 (1995) 54C-59C
40. Crouse III J.R., Byington R.P., Bond M.G., et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 75 (1995) 455-459
41. Hodis H.N., Mack W.J., LaBree L., et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. Ann Intern Med 124 (1996) 548-556
42. MacMahon S., Sharpe N., Gamble G., et al. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation 97 (1998) 1784-1790
43. de Groot E., Jukema J.W., Montauban van Swijndregt A.D., et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol 31 (1998) 1561-1567
44. Furberg C.D., Adams Jr. H.P., Applegate W.B., et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic carotid Artery Progression Study (ACAPS) Research Group. Circulation 90 (1994) 1679-1687
45. Hedblad B., Wikstrand J., Janzon L., Wedel H., and Berglund G. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 103 (2001) 1721-1726
46. Mercuri M., Bond M.G., Sirtori C.R., et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 101 (1996) 627-634
47. Salonen R., Nyyssonen K., Porkkala E., et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 92 (1995) 1758-1764
48. Crouse III J.R., Raichlen J.S., Riley W.A., et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 297 (2007) 1344-1353
49. Duivenvoorden R., Nederveen A.J., de Groot E., and Kastelein J.J. Atherosclerosis imaging as a benchmark in the development of novel cardiovascular drugs. Curr Opin Lipidol 18 (2007) 613-621
50. Deanfield J.E., Halcox J.P., and Rabelink T.J. Endothelial function and dysfunction: testing and clinical relevance. Circulation 115 (2007) 1285-1295
51. Corretti M.C., Anderson T.J., Benjamin E.J., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39 (2002) 257-265
52. Donald A.E., Halcox J.P., Charakida M., et al. Methodological approaches to optimize reproducibility and power in clinical studies of flow-mediated dilation. J Am Coll Cardiol 51 (2008) 1959-1964
53. Yeboah J., Crouse J.R., Hsu F.C., Burke G.L., and Herrington D.M. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation 115 (2007) 2390-2397
54. Lieberman E.H., Gerhard M.D., Uehata A., et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 121 (1994) 936-941
55. Muiesan M.L., Salvetti M., Monteduro C., et al. Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension. Hypertension 33 (1999) 575-580
56. Treasure C.B., Klein J.L., Weintraub W.S., et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332 (1995) 481-487
57. Jodoin I., Bussieres L.M., Tardif J.C., and Juneau M. Effect of a short-term primary prevention program on endothelium-dependent vasodilation in adults at risk for atherosclerosis. Can J Cardiol 15 (1999) 83-88
58. Raitakari O.T., Ronnemaa T., Jarvisalo M.J., et al. Endothelial function in healthy 11-year-old children after dietary intervention with onset in infancy: the Special Turku Coronary Risk Factor Intervention Project for children (STRIP). Circulation 112 (2005) 3786-3794
59. Cai J., Hatsukami T.S., Ferguson M.S., et al. In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque: comparison of high-resolution, contrast-enhanced magnetic resonance imaging and histology. Circulation 112 (2005) 3437-3444
60. Kerwin W.S., O'Brien K.D., Ferguson M.S., Polissar N., Hatsukami T.S., and Yuan C. Inflammation in carotid atherosclerotic plaque: a dynamic contrast-enhanced MR imaging study. Radiology 241 (2006) 459-468
61. Crowe L.A., Gatehouse P., Yang G.Z., et al. Volume-selective 3D turbo spin echo imaging for vascular wall imaging and distensibility measurement. J Magn Reson Imaging 17 (2003) 572-580
62. Wentzel J.J., Corti R., Fayad Z.A., et al. Does shear stress modulate both plaque progression and regression in the thoracic aorta? Human study using serial magnetic resonance imaging. J Am Coll Cardiol 45 (2005) 846-854
63. Yarnykh V.L., Terashima M., Hayes C.E., et al. Multicontrast black-blood MRI of carotid arteries: comparison between 1.5 and 3 Tesla magnetic field strengths. J Magn Reson Imaging 23 (2006) 691-698
64. Duivenvoorden R, de Groot E, Elsen BM, et al. In vivo quantification of carotid artery wall dimensions: 3.0 Tesla MRI versus B-mode ultrasound imaging. Circulation Cardiovascular Imaging; in press.
65. Corti R., Fayad Z.A., Fuster V., et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 104 (2001) 249-252
66. Corti R., Fuster V., Fayad Z.A., et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 106 (2002) 2884-2887
67. Lima J.A., Desai M.Y., Steen H., Warren W.P., Gautam S., and Lai S. Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy. Circulation 110 (2004) 2336-2341
68. Yonemura A., Momiyama Y., Fayad Z.A., et al. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. J Am Coll Cardiol 45 (2005) 733-742
69. Lee J.M.S., Wiesmann F., Shirodaria C., et al. Early changes in arterial structure and function following statin initiation: quantification by magnetic resonance imaging. Atherosclerosis 197 (2008) 951-958
70. Zhao X.Q., Yuan C., Hatsukami T.S., et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol 21 (2001) 1623-1629
71. Underhill H.R., Yuan C., Zhao X.Q., et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J 155 (2008) 584-588
72. Jaffer F.A., O'Donnell C.J., Larson M.G., et al. Age and sex distribution of subclinical aortic atherosclerosis: a magnetic resonance imaging examination of the Framingham Heart Study. Arterioscler Thromb Vasc Biol 22 (2002) 849-854